"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is ...

Patients with a type of prostate cancer known as metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Delays in treating a patient with an aggressive form of prostate cancer more than likely contributed to his disease advancing ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

They use the body's own immune system to detect and kill cancer cells "Immunotherapies have been very promising and has ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...